{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:25:43Z","timestamp":1786955143813,"version":"build-2736575974"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    Urothelial carcinoma in young patients is exceedingly rare, and their molecular oncogenesis is not well understood. In this study, we investigated the frequencies of\n                    <jats:italic toggle=\"yes\">HRAS, TERT<\/jats:italic>\n                    promoter, and\n                    <jats:italic toggle=\"yes\">FGFR3<\/jats:italic>\n                    mutations in a cohort of 31 urothelial neoplasms occurring in children and young adults, to understand their molecular characteristics and underpinnings. Thirty-one urothelial neoplasms were identified in patients less than 30 years of age. Genomic DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissue sections. Real-time polymerase chain reaction was used to detect\n                    <jats:italic toggle=\"yes\">HRAS, TERT<\/jats:italic>\n                    promoter, and\n                    <jats:italic toggle=\"yes\">FGFR3<\/jats:italic>\n                    mutations, and the results were analyzed using high-resolution fluorescence melting curves. The cohort included 2 urothelial papillomas, 1 papillary urothelial neoplasm of low malignant potential (PUNLMP), 23 noninvasive low-grade papillary urothelial carcinomas, and 5 noninvasive high-grade papillary urothelial carcinomas. The patients\u2019 mean age was 18 years old, and the male-to-female ratio was 1.4:1.\n                    <jats:italic toggle=\"yes\">HRAS<\/jats:italic>\n                    mutation was detected in 55.2% (16\/29) of the premalignant\/malignant cases and in 100% (2\/2) of the urothelial papillomas, with an overall incidence of 58.1%.\n                    <jats:italic toggle=\"yes\">TERT<\/jats:italic>\n                    promoter mutation was detected in 37.9% (11\/29) of PUNLMP and malignant cases, and in none of the benign cases.\n                    <jats:italic toggle=\"yes\">FGFR3<\/jats:italic>\n                    mutation was not detected in any of the cases. Urothelial carcinomas occurring in children and young adults exhibit a distinct molecular profile compared with those in older patients, characterized by a higher frequency of\n                    <jats:italic toggle=\"yes\">HRAS<\/jats:italic>\n                    mutations and a significantly lower prevalence of\n                    <jats:italic toggle=\"yes\">TERT<\/jats:italic>\n                    promoter and\n                    <jats:italic toggle=\"yes\">FGFR3<\/jats:italic>\n                    alterations.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002566","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:00:21Z","timestamp":1778842821000},"page":"999-1006","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Urothelial Carcinoma in Children and Young Adults is Characterized by Higher Frequency of HRAS Mutations and Lower Prevalence of TERT Promoter and FGFR3 Mutations"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-5293","authenticated-orcid":false,"given":"Liang","family":"Cheng","sequence":"first","affiliation":[{"name":"Pathology, Laboratory Medicine, and Surgery, The Legorreta Cancer Center at Brown University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Min","family":"Tan","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University, and Brown University Health, Providence, RI"},{"name":"Pathology, National University Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lopez-Beltran","sequence":"additional","affiliation":[{"name":"Morphologic Sciences, Cordoba University, Medical School, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Montironi","sequence":"additional","affiliation":[{"name":"Molecular Medicine and Cell Therapy Foundation, Polytechnic University of the Marche Region, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeboye O.","family":"Osunkoya","sequence":"additional","affiliation":[{"name":"Pathology and Urology, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cheng","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Amin","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University, and Brown University Health, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Cimadamore","sequence":"additional","affiliation":[{"name":"Medicine (DMED), Institute of Pathologic Anatomy, Udine University, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pediatrics and Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"R1-20260817","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.urology.2025.11.242","article-title":"Clinical characteristics, recurrence, and survival for children and young adults with urothelial cancer: a systematic review","volume":"208","author":"Aponte-Colon","year":"2026","journal-title":"Urology"},{"key":"R2-20260817","doi-asserted-by":"crossref","first-page":"26 e1","DOI":"10.1016\/j.jpurol.2014.08.008","article-title":"Bladder urothelial neoplasms in pediatric age: experience at three tertiary centers","volume":"11","author":"Berrettini","year":"2015","journal-title":"J Pediatr Urol"},{"key":"R3-20260817","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.5858\/arpa.2012-0322-OA","article-title":"Urothelial tumors of the urinary bladder in young patients: a clinicopathologic study of 59 cases","volume":"137","author":"Stanton","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"R4-20260817","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.urolonc.2010.08.003","article-title":"Unique clinicopathologic and molecular characteristics of urinary bladder tumors in children and young adults","volume":"31","author":"Williamson","year":"2013","journal-title":"Urol Oncol"},{"key":"R5-20260817","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jpurol.2019.06.013","article-title":"Urothelial cell carcinoma of the bladder in pediatric patients: a systematic review and data analysis of the world literature","volume":"15","author":"Rezaee","year":"2019","journal-title":"J Pediatr Urol"},{"key":"R6-20260817","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/cancers12020307","article-title":"Genomic landscape of young-onset bladder cancer and its prognostic implications on adult bladder cancer","volume":"12","author":"Im","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R7-20260817","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4103\/UA.UA_60_18","article-title":"Lower urinary tract symptoms and bladder cancer in children: the hidden scenario","volume":"11","author":"Karatzas","year":"2019","journal-title":"Urol Ann"},{"key":"R8-20260817","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12894-025-01831-6","article-title":"Pediatric papillary urothelial neoplasm: 18-year single-center experience in diagnosis and treatment","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Urol"},{"key":"R9-20260817","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/cancers17050845","article-title":"Urothelial bladder carcinoma in young and elderly patients: pathological insights and age-related variations","volume":"17","author":"T\u0103tar","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R10-20260817","doi-asserted-by":"crossref","first-page":"105677","DOI":"10.1016\/j.jpurol.2025.11.015","article-title":"Urothelial cell carcinoma of the bladder in pediatric patients: a comparison with adults from the National Cancer Database","volume":"22","author":"Weir","year":"2026","journal-title":"J Pediatr Urol"},{"key":"R11-20260817","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/PAP.0b013e318204c0cf","article-title":"Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management","volume":"18","author":"Paner","year":"2011","journal-title":"Adv Anat Pathol"},{"key":"R12-20260817","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/modpathol.2014.48","article-title":"Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations","volume":"27","author":"Williamson","year":"2014","journal-title":"Mod Pathol"},{"key":"R13-20260817","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fped.2019.00385","article-title":"Bladder urothelial carcinoma in a child: case report and review of literature","volume":"7","author":"Oda","year":"2019","journal-title":"Front Pediatr"},{"key":"R15-20260817","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/1389202916666151014221954","article-title":"Genetics of bladder malignant tumors in childhood","volume":"17","author":"Zangari","year":"2016","journal-title":"Curr Genomics"},{"key":"R16-20260817","first-page":"437","article-title":"Genetic profiling and pathway analysis in bladder carcinoma: Implications for therapeutic targeting","volume":"41","author":"Vasishta","year":"2025","journal-title":"Turk J Surg"},{"key":"R17-20260817","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/path.2075","article-title":"Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger","volume":"211","author":"Wild","year":"2007","journal-title":"J Pathol"},{"key":"R18-20260817","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.juro.2010.03.131","article-title":"Low frequency of epigenetic events in urothelial tumors in young patients","volume":"184","author":"Owen","year":"2010","journal-title":"J Urol"},{"key":"R19-20260817","doi-asserted-by":"crossref","first-page":"91 e1","DOI":"10.1016\/j.jpurol.2015.08.020","article-title":"H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases","volume":"12","author":"Castillo-Martin","year":"2016","journal-title":"J Pediatr Urol"},{"key":"R20-20260817","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/ejhg.2013.251","article-title":"HRAS mutations in bladder cancer at an early age and the possible association with the Costello Syndrome","volume":"22","author":"Beukers","year":"2014","journal-title":"Eur J Hum Genet"},{"key":"R21-20260817","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1126\/science.1260200","article-title":"TERT promoter mutations and telomerase reactivation in urothelial cancer","volume":"347","author":"Borah","year":"2015","journal-title":"Science"},{"key":"R22-20260817","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/his.12920","article-title":"Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change","volume":"69","author":"Cheng","year":"2016","journal-title":"Histopathology"},{"key":"R23-20260817","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2016.12.008","article-title":"TERT promoter mutations occur frequently in urothelial papilloma and papillary urothelial neoplasm of low malignant potential","volume":"71","author":"Cheng","year":"2017","journal-title":"Eur Urol"},{"key":"R24-20260817","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.euf.2017.03.007","article-title":"Small cell carcinomas of the urinary bladder and prostate: TERT promoter mutation status differentiates sites of malignancy and provides evidence of common clonality between small cell carcinoma of the urinary bladder and urothelial carcinoma","volume":"4","author":"Priemer","year":"2018","journal-title":"Eur Urol Focus"},{"key":"R25-20260817","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.humpath.2022.06.005","article-title":"Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management","volume":"133","author":"Cheng","year":"2023","journal-title":"Hum Pathol"},{"key":"R26-20260817","doi-asserted-by":"crossref","first-page":"100151","DOI":"10.1016\/j.modpat.2023.100151","article-title":"Frequent telomerase reverse transcriptase promoter and fibroblast growth factor receptor 3 mutations support the precursor nature of papillary urothelial hyperplasia of the urinary bladder","volume":"36","author":"Cheng","year":"2023","journal-title":"Mod Pathol"},{"key":"R27-20260817","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.humpath.2022.08.006","article-title":"The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges","volume":"133","author":"Mohanty","year":"2023","journal-title":"Hum Pathol"},{"key":"R28-20260817","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/modpathol.2009.28","article-title":"FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations","volume":"22","author":"Lott","year":"2009","journal-title":"Mod Pathol"},{"key":"R29-20260817","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/s41379-021-00776-z","article-title":"Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications","volume":"34","author":"Cheng","year":"2021","journal-title":"Mod Pathol"},{"key":"R30-20260817","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/PAS.0000000000002171","article-title":"RAS family gene mutations, clinicopathological features, and spread patterns of inverted urothelial papilloma of the bladder","volume":"48","author":"Kitahama","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"R31-20260817","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/path.5261","article-title":"Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder","volume":"248","author":"Isharwal","year":"2019","journal-title":"J Pathol"},{"key":"R32-20260817","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.humpath.2014.06.003","article-title":"HRAS mutations are frequent in inverted urothelial neoplasms","volume":"45","author":"McDaniel","year":"2014","journal-title":"Hum Pathol"},{"key":"R33-20260817","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3390\/cancers16081572","article-title":"The genomic, transcriptomic, and immunologic landscape of HRAS mutations in solid tumors","volume":"16","author":"Kareff","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R34-20260817","first-page":"108","article-title":"Analysis of FGFR3 and HRAS genes in patients with bladder cancer","volume":"34","author":"Homami","year":"2020","journal-title":"Med J Islam Repub Iran"},{"key":"R35-20260817","doi-asserted-by":"crossref","first-page":"614","DOI":"10.5306\/wjco.v11.i8.614","article-title":"Mutational analysis of RAS hotspots in patients with urothelial carcinoma of the bladder","volume":"11","author":"Tripathi","year":"2020","journal-title":"World J Clin Oncol"},{"key":"R36-20260817","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.juro.2009.01.011","article-title":"Activation of RAS family genes in urothelial carcinoma","volume":"181","author":"Boulalas","year":"2009","journal-title":"J Urol"},{"key":"R37-20260817","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2025.04.005","article-title":"Clinical and genomic landscape of FGFR3 alterations across different stages of urothelial cancer","volume":"77","author":"Haas","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"R38-20260817","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41588-024-02030-z","article-title":"Comprehensive genomic characterization of early-stage bladder cancer","volume":"57","author":"Prip","year":"2025","journal-title":"Nat Genet"},{"key":"R39-20260817","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.urology.2015.12.032","article-title":"Transitional cell carcinoma in the pediatric patient: a review of the literature","volume":"91","author":"Chu","year":"2016","journal-title":"Urology"},{"key":"R40-20260817","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/cge.14111","article-title":"Prevalence of bladder cancer in Costello syndrome: new insights to drive clinical decision-making","volume":"101","author":"Leoni","year":"2022","journal-title":"Clin Genet"},{"key":"R41-20260817","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1038\/s41416-023-02229-7","article-title":"Cancer in Costello syndrome: a systematic review and meta-analysis","volume":"128","author":"Astiazaran-Symonds","year":"2023","journal-title":"Br J Cancer"},{"key":"R42-20260817","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"R43-20260817","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","article-title":"Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome","volume":"65","author":"Allory","year":"2014","journal-title":"Eur Urol"},{"key":"R44-20260817","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/his.15555","article-title":"Molecular pathology of bladder cancer","volume":"88","author":"Lopez-Beltran","year":"2026","journal-title":"Histopathology"},{"key":"R45-20260817","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/path.5307","article-title":"Distinct mutational landscape of inverted urothelial papilloma","volume":"249","author":"Akgul","year":"2019","journal-title":"J Pathol"},{"key":"R46-20260817","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1158\/1541-7786.MCR-16-0003","article-title":"Understanding TERT promoter mutations: a common path to immortality","volume":"14","author":"Bell","year":"2016","journal-title":"Mol Cancer Res"},{"key":"R47-20260817","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.4161\/cc.24662","article-title":"Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma","volume":"12","author":"Liu","year":"2013","journal-title":"Cell Cycle"},{"key":"R48-20260817","doi-asserted-by":"crossref","first-page":"915","DOI":"10.7150\/jca.15006","article-title":"TERT core promoter mutations in early-onset bladder cancer","volume":"7","author":"Giedl","year":"2016","journal-title":"J Cancer"},{"key":"R49-20260817","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/his.70060","article-title":"Urologic surgical pathology in the era of precision medicine","volume":"88","author":"Cheng","year":"2026","journal-title":"Histopathology"},{"key":"R51-20260817","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.humpath.2010.07.007","article-title":"Bladder cancer: translating molecular genetic insights into clinical practice","volume":"42","author":"Cheng","year":"2011","journal-title":"Hum Pathol"},{"key":"R52-20260817","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2013.08.008","article-title":"Biomarkers in bladder cancer: translational and clinical implications","volume":"89","author":"Cheng","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"R53-20260817","doi-asserted-by":"crossref","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:00:26Z","timestamp":1786953626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002566","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"2026-02-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}